Osteosarcoma represents the most frequent malignant primary bone tumor, which mainly occurs in children and adolescents and causing high mortality. To date, despite significant advancements in the diagnosis and treatment of the cancer, long-term survival in both localized and metastatic osteosarcoma is still stagnated. Thus, conventional therapy is not fully adequate for osteosarcoma treatment and novel therapeutic approaches are required to improve outcomes.
Antibody-drug conjugates (ADCs) as a targeted immunotherapy display significant advantages in cancer treatment, which also have shown great potential for the osteosarcoma treatment currently. Creative Biolabs is committed to all kinds of bio-conjugation for many years, and we have integrated technology platforms for specific ADCs development. As your value-added partner in biopharmaceutical drug development, we offers a complete range of ADCs construction services against osteosarcoma.
Osteosarcoma is the most common primary malignant bone tumor arising from the metaphysis of long bones. Osteosarcoma mainly occurs in teenagers and young adults, but it can also occur in younger children and older adults. Usually, symptoms of osteosarcoma include swelling near a bone, bone or joint pain and unexplained bone injury or bone break. To date, the precise cause of the cancer is not clear. Some risk factors may contribute to the disease such as the previous treatment with radiation therapy, certain inherited or genetic conditions and so on. Currently, major therapy strategies for osteosarcoma include surgery to remove the cancer cells, limb-sparing surgery to remove the tumor and tissue, amputation, rotationplasty, chemotherapy and radiation therapy.
Fig.1 Osteogenesis and osteosarcomagenesis. (Lin, 2017)
Treatment for the osteosarcoma is generally based on the tumor entity, tumor stage, age, gender, general condition, quality of life, life expectancy, etc. Some conventional therapeutic approaches remain the main options including the surgery, chemotherapy, and palliative radiotherapy. However, some innovative therapy methods are displaying unique advantages and promise.
Fig.2 Structures of glembatumumab vedotin (CDX‑011).
Creative Biolabs has extensive experience in ADCs development with expertise in antibody generation, linker-payload production and bioconjugate design and generation. We now provide a full range of ADCs preparation services for osteosarcoma treatment with developed and mature conjugation protocols. Creative Biolabs’ custom conjugation services allow the generation of high quality conjugates optimized to meet your specifications, and we promise to provide stable, reproducible conjugates efficiently within a minimal timescale.
Target of ADC development for prostate cancer:
If you are interested in our services, please feel free to contact us for more detailed information.
Reference
For Research Use Only. NOT FOR CLINICAL USE.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Contact us